BioSpace News Archive

Thirty-five abstracts with clinical trial data to be presented, featuring findings across psoriatic arthritis (PsA), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) Sixteen abstracts focus on TREMFYA® (guselkumab) in adults with active PsA, including 52-week safety and efficacy data, spinal disease-related endpoints, as well as analyses that highlight patient-reported outcome measures including fatigue

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the company will arrange a virtual capital markets day for investors, analysts and journalists on November 30 th , 2020. The program will be published on the company’s website during the week of November 23 at: www.oncopeptides.com/en/calendar/ Oncopeptide

Sonata Scientific LLC, a developer of advanced air purification and antimicrobial products, has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $256,000 to conduct research

Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on womens intimate health, today announced that it will report its third quarter 2020 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, November 12, 2020.

NANO-X IMAGING LTD (NASDAQ: NNOX) (“ Nanox ” or the “ Company ”), an innovative medical imaging technology company, announced today that Ran Poliakine, Chairman and Chief Executive Officer and other members of the leadership team will be participating in three upcoming investor conferences. Presentation details: Event: Berenberg US CEO Conference 2020 Date: Thursday, November 12, 2020 Time: 9:00 AM ET Event

OPTEC International, Inc announced that it has successfully secured a fully executed definitive agreement for the supply of Brand Specific Personal Protection Equipment products for a large International Commodities Consortium totaling in excess of $2 Billion Dollars US.

Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announced that it has filed its FDA submission for the T-Cell Select reagent kit.

- Nearly 40 abstracts on eight investigational and approved products across 11 cancer types to be presented - New disease-free survival results from the CAPTIVATE study, ibrutinib (IMBRUVICA®) + venetoclax (VENCLEXTA®/VENCLYXTO®) combination regimen for chronic lymphocytic leukemia (CLL) - New data from a 5-year analysis of the MURANO study of venetoclax (VENCLEXTA®/ VENCLYXTO®) in CLL

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that study investigators will present data from the LOXO-305 development program at the American Society of Hematology (ASH) Annual Meeting to be held December 5-8, 2020 . LOXO-305 is an investigational, highly selective, n

As a multi-cytokine inhibitor, BNZ-1 is a novel immuno-oncology drug that integrates inhibition of malignant cells, activation of tumor immunity, and suppression of inflammation